Análisis Argos
BAX
BAXCara
Baxter International Inc. · Healthcare
US$ 22.65
precio al 2026-07-04
Valor justo Argos*
US$ 16–17
vs. su valor justo
43% por encima
Score Argos
34/100
LA RESPUESTA
El mercado le pide crezca 14% al año — más de lo que ha demostrado (0.1%). Estás pagando un futuro que todavía no probó: el margen de error es mínimo.
Recompensas
Sin recompensas destacadas.
Riesgos
!El precio pide más crecimiento del que la empresa ha demostrado.
!Balance frágil: la deuda pesa sobre el negocio.
!Crecimiento estancado o en baja.
VALOR2/6FUTURO1/6PASADO1/6SALUD2/6DIVIDENDO3/6
El Iris de calidad
VALOR2/6FUTURO1/6PASADO1/6SALUD2/6DIVIDENDO3/6
ValorCerca de su valor justo
FuturoIngresos estancados o cayendo
PasadoHistorial débil
SaludBalance razonable
DividendoRetorno al accionista moderado
Score Argos34de 100Cara
Ingresos6%
US$ 11.2 B
Margen operativo2800%
-2.7%
Flujo de caja libre43%
US$ 0.3 B
Deuda neta
US$ 8 B
Lo esencial, sin ruido
Cap. de mercadoUS$ 11.7B
P/E
EV/EBITDA29.3x
FCF yield2.8%
ROIC-2.2%
Margen operativo-2.7%
Crecim. ingresos+5.7%/año
Piotroski F4/9
Competidores

Los rivales, con el mismo ojo

El Iris de calidad de cada competidor, lado a lado. Tocá uno para ver su análisis.

Novedades

Noticias recientes

gurufocus.com · 22 jun
Baxter Publishes 2025 Sustainability Report Highlighting Refreshed Strategy, Ongoing Commitment to Drive Meaningful Impact
Baxter International Inc. (NYSE: BAX), a global medtech leader, today published its newly renamed [url="]2025 Sustainability Report[/url], highlighting the comp
businesswire.com · 22 jun
Baxter Publishes 2025 Sustainability Report Highlighting Refreshed Strategy, Ongoing Commitment to Drive Meaningful Impact
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today published its newly renamed 2025 Sustainability Report, highlighting the company's progress and refreshed approach to advancing a sustainable and responsible business model. “As we shape Baxter's next chapter, our focus remains clear: making a meaningful difference for patients, customers and communities while working to create long‑term value for all stakeholders,” said Andrew Hider, presiden.
zacks.com · 19 jun
Baxter's Unit Synovis MCA to Lead Global Rollout of the SHIYA Platform
BAX gains as Synovis MCA signs a multi-year deal to commercialize MediThinQ's SHIYA 3D surgical visualization platform worldwide.
zacks.com · 16 jun
Reasons to Retain Baxter International Stock in Your Portfolio for Now
BAX is pursuing a broad turnaround as innovation, resilient demand, and AI integration support recovery despite regulatory risks and margin pressure.
seekingalpha.com · 9 jun
Baxter International Inc. (BAX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Baxter International Inc. (BAX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
seekingalpha.com · 13 may
Baxter International Inc. (BAX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Baxter International Inc. (BAX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
marketbeat.com · 9 may
Baxter International Shareholders Approve Board Slate, Pay and Incentive Plan at Annual Meeting
Baxter International NYSE: BAX held its 2026 annual meeting of stockholders by webcast, with shareholders giving preliminary approval to all five proposals presented by the company, including the election of nine directors, executive compensation, auditor ratification, an amended incentive plan and a change related to board size.
seekingalpha.com · 7 may
Baxter International Still Has A Path To Upside
In recent years, stocks like Baxter International have underperformed: most low-growth, high-debt, struggling names have been bad investments at basically any price. Concerns are real, and early missteps under new CEO Andrew Hider haven't helped. But valuation is attractive not just on an absolute basis but also relative to the outlook, and Q1 results seemed helpful to the bull case.

* Valor justo Argos: estimación educativa del valor intrínseco según el propio flujo de caja de la empresa y su capacidad de crecimiento — no un precio objetivo ni una recomendación. Esto es información y educación, no asesoría de inversión. Rendimiento pasado no garantiza resultados futuros.